Cannabis and Nicotine Before Spine Fusion: Insights from a Large Cohort Study
A June 2026 cohort study of 144,488 patients examined cannabis use before spine surgery and found it linked to higher pain, psychiatric, and opioid-related complications. Documented cannabis use, especially combined with nicotine, identified a…
Cannabis and Coronary Thrombosis: Clinical Insights from a New Case Report
A 2026 case report highlights a cannabis cardiovascular safety signal involving extensive coronary thrombosis in a young chronic cannabis user. The report proposes a cannabinoid-receptor-mediated mechanism but cannot prove causation. This safety signal…
Cannabinoids in Substance Use Disorders: What a New Systematic Review Actually Found
Cannabinoids and substance use disorders were the focus of a 2026 systematic review spanning 97 studies and nearly 42,000 participants. The review found cannabinoids more often relieved short-term symptoms like craving and withdrawal than they improved…
Cannabis Oil and Fibromyalgia: Clinical Benefit Without Blood Biomarker Change
This oral THC CBD fibromyalgia trial tested a 1:1 THC:CBD oil over 16 weeks in women with fibromyalgia. Despite no changes in peripheral blood endocannabinoid biomarkers, clinical benefits were reported. The findings suggest central nervous system…
What the New Trial Reveals About Acute Cannabis Inflammation Response
The acute cannabis inflammation response was studied in a July 2026 trial examining high-THC exposure effects. Results showed a stronger inflammatory cytokine increase without measurable insulin sensitivity changes. This acute biomarker trial informs…
CED Cannabis Science Digest: Clinical Evidence on Mental Health and Cannabis
This digest presents cannabis mental health clinical evidence from three July 2026 peer-reviewed papers. It highlights important context on antidepressant co-use, adolescent depression, and high-THC product risk. These findings support educational…
1 in 3 Cannabis Users in Treatment Had ADHD: What the New Meta-Analysis Shows
ADHD and cannabis use often overlap, and a July 2026 systematic review and meta-analysis of 84 studies and 34,036 adults in treatment settings put a number on it. People who use cannabis had the highest ADHD prevalence of any subgroup at 33 percent, well…
CED Cannabis Science Digest: 3 CBD and Cannabinoid Product-Safety Signals Worth Watching
CBD and cannabinoid product signals: Three July 2026 papers sharpen how readers interpret CBD supplements, mislabeled CBD food products, and Delta-8 or Delta-9 cannabinoid detection. These are context and caution signals, not treatment-proof claims. The…
Can Low-Dose CBD Feel Psychoactive? What the New Healthy-Volunteer Trial Actually Found
A 2026 randomized crossover study found that a 200 mg CBD pleasant drug effect was perceptible after oral administration in healthy occasional cannabis users. Lower doses did not produce this effect. This finding challenges the notion that low-dose CBD…
CBD for Pericarditis: What the New JAHA Trial Shows
CBD for recurrent pericarditis produced early pain and inflammation signals in a 27-person Phase II pilot trial. Most participants entering the extension remained recurrence-free while standard medications were tapered, but the study had no placebo group…